SCHEMBL24026378

SCHEMBL24026378

CCCC(C)n1cnc2c(=O)n(C)c(N)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 1/20 0.45
▸ ADORA2A P29274 2/20 0.41
▸ ADORA2B P29275 2/20 0.41
▸ ADORA1 P30542 2/20 0.41
▸ CDK1 P06493 3/20 0.38
▸ CDK2 P24941 3/20 0.38
▸ CCNB1 P14635 2/20 0.38
▸ CCNE1 P24864 2/20 0.38
▸ TSHR P16473 3/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ GAA P10253 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ ADA P00813 5/20 0.34
▸ PDE2A O00408 3/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25911374 0.89 ADORA2A (0.52) SLC29A1ADORA2AADORA2BADORA1CDK1
SCHEMBL17863687 0.83 CDK2 (0.54) ADORA2AADORA2BADORA1CDK1CDK2
SCHEMBL18479940 0.76 HPRT1 (0.52) SLC29A1TSHRALDH1A1HSD17B10CYP3A4
SCHEMBL21264900 0.75 CDK1 (0.54) ADORA2AADORA2BADORA1CDK1CDK2
SCHEMBL23710627 0.74 CDK1 (0.36) ADORA2AADORA2BADORA1CDK1CDK2
SCHEMBL15313370 0.74 CDK1 (0.49) ADORA2AADORA2BADORA1CDK1CDK2
SCHEMBL27748107 0.73 CDK1 (0.54) SLC29A1ADORA2AADORA2BADORA1CDK1
SCHEMBL18512915 0.72 AHCY (0.40) CDK1CDK2CCNB1CCNE1ALDH1A1
SCHEMBL23619296 0.71 HPRT1 (0.46) SLC29A1ADORA2AADORA2BADORA1LMNA
SCHEMBL24474429 0.71 KDM4E (0.39) ADORA2AADORA2BADORA1CDK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11208414-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2021-12-28 — — US disclosed
US-11174261-B2 — — 2021-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174261-B2 — ENTPD5, NT5E, ENTPD1 SLC29A1 78/4885ADORA2A 9/4885ADORA2B 35/4885
US-11208414-B2 Ectonucleotidase inhibitors and methods of use thereof ENTPD5, NT5E, ENTPD1 SLC29A1 71/4885ADORA2A 11/4885ADORA2B 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback